Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shenzhen Hepalink Pharmaceutical Group has entered a strategic distribution agreement with Zhejiang Yongtai Pharmaceutical to commercialize Gabapentin capsules in the U.S. market. This move aligns with Hepalink’s international expansion strategy, leveraging their established sales networks to tap into the $463 million U.S. market for Gabapentin. The partnership highlights Hepalink’s marketing capabilities and aims to boost its presence in overseas markets.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.